Litcius/Paper detail

1,2,4-Triazole-based anticonvulsant agents with additional ROS scavenging activity are effective in a model of pharmacoresistant epilepsy

Barbara Kaproń, Robert Czarnomysy, Mariusz Wysokiński, Rudolf Andrýs, Kamil Musílek, Andrea Angeli, Claudiu T. Supuran, Tomasz Plech

2020Journal of Enzyme Inhibition and Medicinal Chemistry60 citationsDOIOpen Access PDF

Abstract

There are numerous studies supporting the contribution of oxidative stress to the pathogenesis of epilepsy. Prolonged oxidative stress is associated with the overexpression of ATP-binding cassette transporters, which results in antiepileptic drugs resistance. During our studies, three 1,2,4-triazole-3-thione derivatives were evaluated for the antioxidant activity and anticonvulsant effect in the 6 Hz model of pharmacoresistant epilepsy. The investigated compounds exhibited 2-3 times more potent anticonvulsant activity than valproic acid in 6 Hz test in mice, which is well-established preclinical model of pharmacoresistant epilepsy. The antioxidant/ROS scavenging activity was confirmed in both single-electron transfer-based methods (DPPH and CUPRAC) and during flow cytometric analysis of total ROS activity in U-87 MG cells. Based on the enzymatic studies on human carbonic anhydrases (CAs), acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), one can assume that the herein investigated drug candidates will not impair the cognitive processes mediated by CAs and will have minimal off-target cholinergic effects.

Topics & Concepts

AnticonvulsantPharmacologyOxidative stressValproic AcidChemistryEpilepsyAcetylcholinesteraseButyrylcholinesteraseAntioxidantBiochemistryAchéEnzymeMedicineBiologyNeuroscienceEnzyme function and inhibitionCholinesterase and Neurodegenerative DiseasesPhenothiazines and Benzothiazines Synthesis and Activities
1,2,4-Triazole-based anticonvulsant agents with additional ROS scavenging activity are effective in a model of pharmacoresistant epilepsy | Litcius